ストックスクリーナーアプリを入手
5.31
5.99%
0.30
プレマーケット:
5.17
-0.14
-2.64%
前日終値:
$5.01
開ける：
$5.03
24時間の取引高:
435.53K
Relative Volume:
0.41
時価総額：
$287.19M
収益：
-
当期純損益:
$-57.44M
株価収益率:
-3.9743
EPS:
-1.3361
ネットキャッシュフロー:
$-56.46M
1週間 パフォーマンス:
+0.76%
1か月 パフォーマンス:
-10.91%
6か月 パフォーマンス:
+23.78%
1年 パフォーマンス:
+12.26%
1日の値動き範囲:
$5.03
$5.49
1週間の範囲:
$4.935
$5.49
52週間の値動き範囲:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.31 | 287.19M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-04 | 開始されました | JP Morgan | Overweight |
| 2026-01-07 | 開始されました | Piper Sandler | Overweight |
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
すべてを表示
Protara Therapeutics Inc (TARA) 最新ニュース
Protara's experimental bladder cancer drug shows encouraging results - MSN
Protara Therapeutics Inc stock faces volatility amid clinical pipeline updates and biotech sector pr - AD HOC NEWS
Form 144 Protara Therapeutics For: 6 March By Investing.com - Investing.com Australia
Aug Ideas: What is the Moat Score of Protara Therapeutics IncMarket Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Sentiment Recap: Whats the profit margin of Protara Therapeutics IncGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February - MarketBeat
Equities Analysts Offer Predictions for TARA Q1 Earnings - MarketBeat
Lifesci Capital Issues Optimistic Estimate for TARA Earnings - MarketBeat
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Published on: 2026-03-12 04:53:12 - baoquankhu1.vn
Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026 - Meyka
TD Cowen reiterates Protara Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TARA Advances Clinical Programs with Key Milestones Ahead - GuruFocus
TARA Secures Financial Stability with $197.9 Million Cash Reserves - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Protara Therapeutics (NASDAQ: TARA) advances TARA-002 and IV Choline into registrational-stage trials - Stock Titan
Protara Therapeutics 2025 Annual Report: Pipeline, Regulatory Strategy, and Commercialization Plans for Cancer and Rare Disease Therapies - Minichart
Protara 10-K: Net loss $57.4M, EPS $(1.34); operating loss widens to $64.5M - TradingView
Protara Therapeutics reports $197.9M cash; Q4 net loss $17.3M, FY loss $57.4M - TradingView
Protara Therapeutics: Q4 Earnings Snapshot - marketscreener.com
TARA: TARA-002 achieved high response rates in NMIBC, with cash runway into 2028 after a major offering - TradingView
BRIEF-Protara Therapeutics Q4 EPS USD -0.37 - TradingView
Bladder cancer drug hits 68% response; Protara sees cash runway into 2028 - Stock Titan
Geopolitics Watch: What is the Moat Score of Protara Therapeutics IncWeekly Trend Recap & Verified Momentum Stock Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Millennium Management LLC Acquires Significant Stake in Protara Therapeutics Inc - GuruFocus
Broker-listed sales by 667, L.P. at TARA (NASDAQ: TARA) reported on Form 144 - Stock Titan
Protara gains as JP Morgan starts at overweight - Seeking Alpha
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
TARA SEC FilingsProtara Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Watch: Can Protara Therapeutics Inc beat the S P 5002025 Sector Review & Weekly High Return Opportunities - baoquankhu1.vn
Millennium group reports 2.76M shares in Protara (TARA) — 5.1% stake - Stock Titan
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Yahoo Finance
TARA PE Ratio & Valuation, Is TARA Overvalued - Intellectia AI
TARA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Protara Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
TARA Should I Buy - Intellectia AI
Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
TARA: TARA-002 advances in NMIBC and LM with promising data and expanding regulatory pathways - TradingView
667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares - Stock Titan
Protara Therapeutics (TARA) Receives a Buy from Piper Sandler - The Globe and Mail
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Protara Therapeutics (TARA) to Release Earnings on Wednesday - MarketBeat
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - MarketBeat
Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus
Protara reports interim results from bladder cancer trial By Investing.com - Investing.com South Africa
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):